General Information of Drug (ID: DMYD37G)

Drug Name
CV8102 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Squamous cell carcinoma 2B60-2D01 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMYD37G

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid-inducible gene-1 (RIG-1) TTVB0O3 DDX58_HUMAN Agonist [2]
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Agonist [2]
Toll-like receptor 8 (TLR8) TT8CWFK TLR8_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Toll-like receptor 7 (TLR7) DTT TLR7 3.7 0.848 -0.152 3.121
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 7 (TLR7) DTT TLR7 3.32E-25 0.44 0.88
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03291002) Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of CureVac.